(RLMD) Relmada Therapeutics - Ratings and Ratios
Gemcitabine, Docetaxel, Sepranolone, Psilocybin
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 107% |
| Value at Risk 5%th | 133% |
| Relative Tail Risk | -24.38% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.09 |
| Alpha | 788.99 |
| CAGR/Max DD | 0.04 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.386 |
| Beta | 0.856 |
| Beta Downside | 0.667 |
| Drawdowns 3y | |
|---|---|
| Max DD | 96.30% |
| Mean DD | 53.98% |
| Median DD | 48.09% |
Description: RLMD Relmada Therapeutics December 23, 2025
Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a U.S. clinical-stage biotech focused on specialty drug delivery platforms, headquartered in Coral Gables, Florida, and operating under the GICS Pharmaceuticals sub-industry.
The company’s lead asset, NDV-01, is a controlled-release intravesical formulation that combines gemcitabine and docetaxel for aggressive non-muscle invasive bladder cancer (NMIBC). It is currently in a Phase 2 trial; NMIBC represents roughly a $2 billion U.S. market, and successful intravesical therapy could capture a meaningful share of that niche.
Relmada’s secondary pipeline includes sepranolone, a neurosteroid epimer of allopregnanolone positioned for Phase 2b trials in Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other conditions linked to heightened GABAergic activity. Additionally, REL-P11, a modified-release psilocybin formulation, has cleared a Phase 1 safety study for metabolic disease indications.
As of the most recent filing, Relmada reported cash and equivalents of approximately $45 million, providing runway for the next 12-18 months of R&D without additional financing. The biotech sector’s average cash burn for Phase 2 programs hovers around $20-$30 million per year, suggesting Relmada’s liquidity is modest but sufficient to advance its current trials, assuming no major cost overruns.
For a deeper dive into RLMD’s valuation metrics and peer comparison, the ValueRay platform offers a concise, data-driven snapshot.
Piotroski VR‑10 (Strict, 0-10) 0.5
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -2.69 (>2.0%) and ΔFCFTA -173.3pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -2.69 (>3.0%) and CFO -40.0m > Net Income -56.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (33.2m) change vs 12m ago 10.00% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.12 (EBITDA TTM -57.2m / Interest Expense TTM 18.0m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 45.22
| 1. Piotroski 0.50pt |
| 2. FCF Yield -12.62% |
| 3. FCF Margin data missing |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda 0.02 |
| 7. RoE -269.5% |
| 8. Revenue Trend data missing |
| 9. EPS Trend 94.43% |
What is the price of RLMD shares?
Over the past week, the price has changed by -9.93%, over one month by -2.16%, over three months by +96.15% and over the past year by +827.27%.
Is RLMD a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RLMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.5 | 34.8% |
| Analysts Target Price | 5.5 | 34.8% |
| ValueRay Target Price | 4.9 | 19.6% |
RLMD Fundamental Data Overview January 04, 2026
P/B = 37.4201
Beta = 0.833
Revenue TTM = 0.0 USD
EBIT TTM = -38.2m USD
EBITDA TTM = -57.2m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -1.38m USD (from netDebt column, last quarter)
Enterprise Value = 316.8m USD (330.7m + (null Debt) - CCE 13.9m)
Interest Coverage Ratio = -2.12 (Ebit TTM -38.2m / Interest Expense TTM 18.0m)
FCF Yield = -12.62% (FCF TTM -40.0m / Enterprise Value 316.8m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 57.8m) / Revenue TTM)
Tobins Q-Ratio = 21.30 (Enterprise Value 316.8m / Total Assets 14.9m)
Interest Expense / Debt = unknown (Interest Expense 1.36m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -30.1m (EBIT -38.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.86 (Total Current Assets 14.9m / Total Current Liabilities 5.19m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 0.02 (negative EBITDA) (Net Debt -1.38m / EBITDA -57.2m)
Debt / FCF = 0.03 (negative FCF - burning cash) (Net Debt -1.38m / FCF TTM -40.0m)
Total Stockholder Equity = 20.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -377.6% (out of range, set to none)
RoE = -269.5% (Net Income TTM -56.2m / Total Stockholder Equity 20.8m)
RoCE = -393.9% (out of range, set to none) (EBIT -38.2m / Capital Employed (Total Assets 14.9m - Current Liab 5.19m))
RoIC = -144.6% (out of range, set to none) (NOPAT -30.1m / Invested Capital 20.8m)
WACC = 9.17% (E(330.7m)/V(330.7m) * Re(9.17%) + (debt-free company))
Discount Rate = 9.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
Fair Price DCF = unknown (Cash Flow -40.0m)
EPS Correlation: 94.43 | EPS CAGR: 116.0% | SUE: 2.23 | # QB: 2
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Year (2026-12-31): EPS=-0.36 | Chg30d=+0.630 | Revisions Net=+1 | Growth EPS=+56.6% | Growth Revenue=+0.0%
Additional Sources for RLMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle